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Duration and extent of penumbra determine the window and brain volume in which interventions may save injured tissue after
stroke. Understanding the penumbra in animals is necessary in order to design models that translate to eﬀective clinical therapies.
New Zealand white rabbits were embolized with aged autologous clot (n = 23) or insoluble microspheres (n = 2 1 ) .T oe x a m i n e
eﬀects of treatment on penumbra, sphere-stroked animals were treated with 3µm microbubbles plus ultrasound (n = 19). Rabbits
were euthanized at 4 or 24hr. Infarct volume was measured following triphenyltetrazolium chloride (TTC) staining of brain
sections. Penumbra was visualized using immunostaining of pimonidazole injected ﬁfteen minutes prior to euthanasia. Potentially
reversible penumbra was present in 14.3% stroked rabbits at 4 hours and 15.7% at 24 hours after embolic stroke and represented
up to 35% of total lost tissue. Intervention at up to 24 hours may beneﬁt a signiﬁcant patient population.
1.Introduction
The degree of neurologic impairment following a stroke de-
pends to a large extent on the volume of brain tissue lost and
the speciﬁc anatomic structures involved. Following local
ischemia, a core population of neurons in a region with ex-
tremely low cerebral blood ﬂow is terminally injured within
a relatively short period of time. Because average time to
hospitalization for stroke is greater than 90 minutes [1], this
central ischemic core cannot, in general, be saved. The re-
gion around the ischemic core with blood ﬂow that is sig-
niﬁcantly reduced, but not below levels compatible with cell
life, is extremely vulnerable to further insult from oxidative
damage, hemorrhage, and inﬂammation during reperfusion.
This sublethally injured penumbra, or area at risk, is even-
tually subsumed into the ischemic core, unless perfusion
improves, and may comprise up to 70% of the total infarct
volume. Stroke therapies that encourage survival of cells in
this region result in better functional outcomes for patients.
Hypoxia within the penumbra may persist for 48 hours
after stroke [2–5]. Whether or not injured cells in the pe-
numbra progress to irreparable damage and cell death is
dependent on small perfusion pressure change [6], and
stroke therapy interventions to increase cerebral microvas-
cular perfusion may have marked clinical impact through
reduction of the amount of hypoxic penumbral tissue that
progresses to cell death. Following reduced blood ﬂow in
stroke, cerebral microvessels undergo adaptations to increase
perfusion, including active dilation to increase blood ﬂow
[7]. Other responses may be maladaptive for the penumbra,
including the release of adhesion molecules and focal loss of
blood-brain barrier to permit inﬂux of inﬂammatory cells
and ﬁbrin [8, 9]. Exposure to tissue factor with resultant
thrombosis can occur where vascular ﬂow is decreased, as
in small vessels in the distribution bed of a large artery [9].
Ultrasound- (US-) facilitated thrombolysis with microbub-
bles (MBs) has been demonstrated to lyse clots in animal
models with and without exogenous thrombolytics such as2 Stroke Research and Treatment
tissue plasminogen activator (tPA) [10–13]. Thrombolytic
therapies may improve perfusion in small vessels, restoring
cerebral blood ﬂow to the penumbra even when recanaliza-
tion of the blocked artery does not occur.
In acute human stroke, clinical imaging with CT perfu-
sion studies or MRI diﬀusion studies provide some measures
of penumbra which are of use in patient selection for ther-
apy. Patients with visible penumbra may respond well to
therapy hours beyond the standard temporal guidelines for
thrombolytic treatment [14].
It is therefore of the utmost importance to determine the
duration of the penumbra in preclinical models of stroke
therapy, as this time represents the window of opportunity
for intervention. Understanding possible diﬀerences in the
development and duration of the penumbra in animal mod-
els is necessary in order to design meaningful animal models
that translate to eﬀective clinical therapies. Pimonidazole
(Hypoxyprobe) has been demonstrated to accurately label
hypoxicregionsinthebrain[15].Theobjecti v esofthisstud y
were to examine the incidence and histologic features of
penumbra in rabbits at 24 hours after infarction using Hyp-
oxyprobe staining in two models of thromboembolic stroke
and to determine eﬀects of treatment with microbubbles and
ultrasound on penumbra.
2.MaterialsandMethods
2.1. Preparation of Embolus. Emboli were prepared by ob-
taining an arterial blood sample (2mL) from a donor rab-
bit. The blood was immediately transferred directly into a
30.5cm length of Butterﬂy pediatric infusion set (no. 4506;
Abbot Hospitals, Inc.; North Chicago, Ill, USA) tubing and
allowed to clot at 37◦C for 3 hours. Following incubation,
but prior to embolization, the clot was expelled from the
tubing into a dish containing physiological saline and sub-
sequently cut into several pieces of 1.0mm in length with
an approximate diameter of 0.6mm. A single clot piece was
drawn into a 3.0mL syringe containing physiological saline
for injection into the ICA with 0.7 to 2.0mL of saline ﬂush.
Care was taken during each ﬂush to ensure that no air bub-
bles were present in the syringe.
2.2. Animal Procedure. All animal procedures were approved
by the Institutional Animal Care and Use Committee. The
surgical and angiographic procedures were previously
described by Brown et al. [16]. Brieﬂy, male and female New
Zealand white rabbits (n = 63; mean body weight =
5.2 ± 0.07kg) were randomly assigned to stroke model
groups and anesthetized. The right side of each rabbit’s head
wasclipped,anddepilatorycreamwasapplied.Asingleplane
C-arm digital subtraction angiography machine (OEC 9800;
GE Healthcare; Salt Lake City, Utah, USA) was utilized for
all angiographic procedures. Baseline subselective internal
carotid artery (ICA) magniﬁcation angiography was per-
formed via the right femoral artery in lateral and frontal
projections to assess the cerebral vasculature of each rabbit.
Rabbits were embolized by injection of 1.0mm blood clot
aged for 3 to 5 hours or 700–900µm microspheres (Embo-
sphere; BioSphere Medical Inc.; Rockland, Mass, USA) in
0.7 to 2.0mL of physiologic saline into the ICA, occluding
branches. One minute following embolization, repeat angi-
ography was performed, and the degree and location of the
arterial occlusion were documented.
For animals in the treatment group, an intravenous
catheter (Instyle-W; Becton Dickinson; Sandy, Utah, USA)
placed into the left ear vein was used for administration of
3µm MB, and transcutaneous pulsed wave (20% duty cycle)
US at 1MHz and 0.8W/cm2 (Sonicator 716; Mettler Elec-
tronics; Anaheim, Calif, USA) was applied for one hour. Fol-
lowing embolization a hand-held 10cm2 therapeutic trans-
ducer was placed in front of the ear and behind the eye and
was coupled to the skin with standard US gel. Positioning of
the US probe was conﬁrmed ﬂuoroscopically.
Rabbits exhibiting a complex origin of the internal ca-
rotid artery preventing subselection and subsequent emboli-
zation on initial angiography (n = 3) and rabbits that did
not undergo angiography (n = 4) were used as unstroked
controlsforpimonidazolestaining.Animalswereeuthanized
via IV pentobarbital overdose at 4 or 24 hours after embol-
ization.
2.3. Measurement of Infarct Volume. Brain was harvested
immediately after euthanasia, chilled in physiologic saline on
melting ice for 60 minutes, and sliced coronally at 0.4cm
intervalsusingamoldandslicingguide(HarvardApparatus)
to assure consistent sectioning. All coronal brain sections
were placed in 1% 2,3,5-triphenyltetrazolium chloride (Sig-
ma-Aldrich; St. Louis, Mo, USA) for 45 minutes at 37◦C,
ﬁxed in 10% formalin, and photographed with a digital cam-
era. Section area and area of infarction were measured using
NIH ImageJ. Infarct and section volumes for each slice were
calculated by multiplying each value by the slice thickness of
4mm. Total brain percent infarct volume was calculated by
dividing the sum of the infarct volumes into the sum of the
section volumes and multiplying by 100%.
2.4. Histopathology. To verify infarct locations each brain
section was ﬁxed in 10% formalin, processed and embedded
into paraﬃn, sectioned at 4µm, and stained with hematox-
ylin and eosin. Each brain coronal section was evaluated
by a veterinary pathologist without knowledge of treatment
group.
Hypoxia in the penumbra may be evaluated using nitro-
imidazole compounds that are reduced in living cells to a
radical anion. In hypoxic cells, this compound irreversibly
binds cellular components and accumulates [16]. The com-
pound does not bind in cells that are not hypoxic, and it
is not metabolized by dead cells in infarcted areas. All
rabbits received 100mg of pimonidazole (Chemicon) IV
15 minutes prior to euthanasia. Following TTC staining,
formalin ﬁxation, and processing as described above, all
sections from each brain were immunolabeled using an anti-
body speciﬁc for pimonidazole (Hypoxyprobe, Chemicon).
Brieﬂy,sectionsweredeparaﬃnizedandantigenretrievalwas
performed via decloaking in tris-buﬀered saline tween-20
(TBST) for 20 minutes. Dako peroxidase block was applied
for10minutes,andsectionswererinsed threetimesinTBST.Stroke Research and Treatment 3
Table 1: Incidence of penumbra.
Model Group Number Time point Incidence of
penumbra
Sphere 3µm MB + US 19 24 4/14 (28.6%)
Sphere Control 14 24 2/14 (14/3%)
Clot Control 23 24 2/23 (8.7%)
Sphere Control 7 4 1/7 (14.3%)
Summary of penumbra incidence by group. No signiﬁcant diﬀerences in
incidence were noted by model (P = 0.62), time point (P = 1.0), or
treatment (P = 0.65).
10% normal goat serum was applied for 30 minutes, and
sections were blotted. Primary monoclonal antibody to
bound pimonidazole (Chemicon) was applied at a 1:50
dilution in Dako diluent with background blocking agents
for 40 minutes. Sections were rinsed three times in TBST,
and secondary Vector antigoat IgG antibody (Vector) diluted
at 1:400 in Dako diluent with background blocking agents
was applied for 30 minutes. Sections were rinsed three
times in TBST. Dako DAB+ was applied for 3 minutes.
Sections were rinsed in TBST and lightly counterstained
with hematoxylin. Brain sections from animals that did not
receive pimonidazole as well as sections stained without
primary antibody are used as negative controls.
Hypoxyprobe- stained slides were digitally scanned using
the Aperio ScanScope T2 (Aperio, Vista, Calif, USA). The
Scanscope produces high resolution slides which may be
viewed and analyzed at magniﬁcations up to 200x. Scanned
slides were examined to detect penumbral staining. Penum-
bra was deﬁned as strong staining (within the upper 90% of
staining intensity) immediately adjacent to and contiguous
with regions of necrosis. Sections were analyzed using mor-
phometrics(ImageScope,Aperio)forareaofpenumbra,area
of infarct, and area of penumbra plus infarct. Lesion size was
measured as the area of the penumbra and the associated
infarct. Penumbral area was measured, and relative size was
given as the percent of total lesion. When multiple infarcted
regions were present within a section, areas for penumbra
and infarcts were summed to give a total area.
2.5. Statistical Analysis. Incidence of penumbra among
groups was compared using Fisher’s exact test as implement-
ed in the statistical software package StatXact. The relation-
ship between penumbra size and percent infarct volume
was assessed using both Pearson and Spearman correlation
coeﬃcients, because of the potential for a nonlinear associa-
tion. A t-test was used to compare the mean percent stroke
volumes between those rabbits with and without penumbra.
Stroke volumes are presented as mean ± standard deviation.
3. Results
Repeat angiography (Figures 1(a) and 1(b)) demonstrated
occlusion in 56 animals. Location of occlusion and numbers
of animals aﬀected are given in the table of Figure 1.T h e
most common type of occlusion on repeat angiography was
single occlusion in the middle cerebral artery (MCA, 26/63).
Additional18animalshadocclusionofboththeACAandthe
middle cerebral artery (MCA). Triple occlusions involving
the cerebral arteries occurred in 3 animals, and the occipital
artery(OA)wasoccludedinoneanimal.Novisibleocclusion
was noted in 7/63 animals, all from the clot control group,
although measurable stroke volume was noted with TTC
stain for these animals, and all had histologic infarction.
Clot model was also associated with fewer MCA and ACA
occlusions (P<0.001, P<0.005, resp.). No other signiﬁcant
diﬀerences were noted for occlusion location and model or
treatment group.
Infarct volume in stroked animals ranged from 0.1% to
18.4%.Unstrokedstainingcontrolrabbitshadstrokevolume
of 0, as expected. Penumbra was evident in Hypoxyprobe-
stained sections as intense staining adjacent to and contigu-
ous with infarct (Figure 2). Brain sections from all animals
exhibited diﬀuse mild hypoxia as demonstrated by weak to
moderate cellular pimonidazole staining, and necrotic tissue
(infarct) was not labeled by pimonidazole (Figure 2(c)).
No labeling was observed in control sections from rabbits
which were not given pimonidazole (Figure 2(d))a n ds e c -
tions stained without primary antibody (data not shown).
Penumbra was observed in 1/7 rabbits (14.3%) at 4 hours
and in 8/51 (15.7%) rabbits at 24h (Table 1).
Incidence of penumbra did not diﬀer with stroke model
(P = 0.62; clot control versus sphere control) or with treat-
ment at 24 hours (P = 0.65; treated versus sphere control,
Table 1). Penumbral staining occurred around both large
and small infarcts, and penumbra size was not signiﬁcantly
correlated with percent infarct volume (P>0.29) at 24
hours. Mean stroke volume percent did not diﬀer between
rabbits with or without penumbra at 24 hours (4.43 ±
4.97 versus 3.60 ± 4.56, resp.; P = 0.64). The average size
of penumbra as a percentage of total lesion (infarct plus
penumbra) at 24 hours was 14% ± 4%. Penumbra ranged
from 0.96% to 35% of the total lesion. Rarely, hypoxic tissue
encircled the ischemic core, but penumbra was more often
eccentric, encompassing only a portion of the circumference
of the ischemic core.
4. Discussion
Preclinical animal models are an important tool in evalua-
tion of potential stroke therapies. It is of vital importance to
understand the pathogenesis of brain loss in these models
and to determine what the optimal window of treatment
therapy is for each model as well as the optimal time for
evaluation of cerebral damage. As stroke develops, hypoxic
tissue peripheral to the ischemic core (penumbra) undergoes
progressive damage culminating in cell death if perfusion
does not improve. This tissue represents the area of the brain
most amenable to stroke therapies and most vulnerable to
reperfusion injury. The volume of the penumbra may be
equal to or greater than the volume of the ischemic core
on CT perfusions or MRI diﬀusion imaging [17]; therefore,
treatments that protect this vulnerable region from further
injury may result in signiﬁcantly reduced ﬁnal stroke volume




Middle cerebral artery 27
Occipital artery 1
MCA+anterior cerebral artery (ACA) 23
MCA+posterior cerebral artery (PCA) 1
MCA+PCA+superior cerebellar artery (SCA) 1
MCA+ACA+PCA 3
No visible occlusion 7
Figure 1:Angiographyresults.Pre-embolizationangiogram(a)demonstratesﬁllingoftheMCA.Occlusionandabsenceofﬁllingareevident
in postembolization angiogram (b). Arrows indicate location of the MCA. Location of occlusion and numbers of animals aﬀected by each
t y p ea r eg i v e ni nt h et a b l e .
In contrast to studies to determine the optimal window
of therapy, studies designed to examine cerebral injury and
eﬀects of treatment on total stroke volume should be eval-
uated at a time point when hypoxic penumbra is no longer
evidentandstrokeismaximallydeveloped.Forthesereasons,
itisvitallyimportanttodeterminethedurationofpenumbra
in preclinical animal models. Although penumbra has been
documented in humans at 48 hours afterinfarction [2, 3],no
penumbra was evident in a rat model at 48 hours [18, 19].
Using in vivo PET imaging of F-ﬂuoromisonidazole in a rat
carotid artery occlusion model, Takasawa et al. [18]d e m -
onstrated that signiﬁcant penumbra is not present at 48
hours after occlusion. However, this study did not examine
timepointsbetween180minutesand48hours.Saitaetal.[4]
found negligible uptake of F-ﬂuoromisonidazole in 4 rats at
22 hours after infarction. Noto et al. [21] used a similar com-
pound, pimonidazole (Hypoxyprobe, Chemicon), to eval-
uate the penumbra in a rat model of focal cerebral ischemia
and found increased Hypoxyprobe labeling in 5/5 animals
at 24 hours after infarction [20, 21]. The objective of this
study was to determine the incidence of hypoxic penumbra
intworabbitthromboembolic strokemodelsandtoexamine
the eﬀects of thrombolytic therapy on penumbra at 24 hours
after infarction.
Penumbra was easily distinguished as clearly deﬁned re-
gions of very intense staining adjacent to and contiguous
with infarcts. This staining pattern was observed in 15.7%
of animals at 24 hours. There is convincing evidence that the
penumbra is likely to succumb to cell death over time and
therefore contribute up to 50% of the total brain loss in
stroke [6, 19]. In the rabbits of this study, the penumbra
representedonaverageapproximately14%ofthetotallesion.
This result is consistent with previously published ﬁndings
in humans and rats [19, 22]. Penumbra was occasionally
circumferential but more often did not completely encircle
infarct. This pattern is consistent with reperfusion gradients
thatdependonavailablecollateralbloodsupply.Thepenum-
bra was very similar in size and shape to penumbra imaged
using 18F ﬂuoromisonidazole PET [18], a compound that
accumulates in hypoxic tissue using the same mechanism as
pimonidazole, and 2-deoxyglucose PET [19] in rats. Despite
some diﬀerences in location of occlusion between groups
on postembolization angiography, no signiﬁcant diﬀerences
were found in incidence of penumbra. This suggests that
persistence of penumbra is independent of type of occlusion.
The observed diﬀerences in location of occlusion be-
tweenclotandspheremodelsmaybeexplainedbyfunctional
diﬀerences in type of embolus It is of particular interest that
all animals without visible occlusion in major arteries but
histologic evidence of stroke were embolized with aged clot.
This suggests that clot may be partially lysed by endogenous
processesduringandimmediatelyfollowingembolization,at
least in some animals, resulting in fragmentation and block-
age of smaller vessels downstream.Stroke Research and Treatment 5
(a) (b)
(c) (d)
Figure 2: Pimonidazole stain identiﬁes penumbra. (a) Intense staining is present in penumbra (arrow) adjacent to infarct (stars), 0.5×
magniﬁcation. (b) Closeup of area within the box demonstrates intense staining adjacent to infarct, 4× magniﬁcation. (c) Diﬀuse weak
staining (arrows) indicates mild hypoxia associated with euthanasia. Infarct does not stain (star.), 0.5× magniﬁcation. Negative control (d).
Although penumbra persisted for 24 hours in some ani-
mals, no eﬀect of treatment with 3µm microbubbles and ul-
trasound on the incidence of penumbra was noted. This
indicates that this treatment exerts protective eﬀects, if any,
onpenumbraatearlytimepoints.However,othertreatments
may have more signiﬁcant eﬀect on penumbra, and further
study is warranted. Currently in the United States, approx-
imately 3% of strokes are treated using IV thrombolytic
therapy applying a 4.5-hour window or using intra- arterial
clot removal applying a 6-hour window [23]. With accurate
penumbra imaging, much later interventions may be suc-
cessfully applied [14]. In this rabbit model 15.7% had sig-
niﬁcant penumbra, potentially curable areas of brain dam-
age even at 24 hours. This suggests that clinical tests for pe-
numbra, CT perfusion, or MRI diﬀusion studies should be
performed regardless of stroke duration to select these pa-
tients who can still proﬁt from intervention at much later
times than currently is the standard of care [24–26]. Our
results suggest that therapy could potentially beneﬁt a much
greater patient population.
Diﬀuse mild cerebral hypoxia, characterized by weak to
moderate, diﬀuse staining with pimonidazole, was evident
in all animals. This staining was not present in control sec-
tions from animals not given pimonidazole or controls
stained without the primary antibody, and it most likely
representsbindingofpimonidazoleinhypoxicbraininduced
by the euthanasia process, which involves sedation followed
by intravenous injection of pentobarbital. To avoid mis-
characterization of this background hypoxia as penumbra,
threshold for penumbra was set at the upper 90% of staining
intensityandincludedonlystainingcontiguouswithinfarcts.
Certainly brain swelling can compromise blood ﬂow in areas
away from the primary infarct. This may have excluded some
areas of actual penumbra by generally underestimating its
volume or presence.
Hypoxic penumbra remained in 15.7% of rabbits at 24
hours. This suggests that a signiﬁcant number of patients
may beneﬁt from additional imaging at 24 hours, with con-
tinued intervention if residual penumbra is present.
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